SPIA
RCKT icon

Steward Partners Investment Advisory’s Rocket Pharmaceuticals RCKT Stock Holding History

Steward Partners Investment Advisory’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.9K Hold
16,340
– – ﹤0.01% 2878
2026
Q1 		$58.5K Hold
16,340
– – ﹤0.01% 2705
2025
Q4 		$57.4K Buy
16,340
+2,500
+18% +$8.56K ﹤0.01% 2600
2025
Q3 		$45.1K Hold
13,840
– – ﹤0.01% 2656
2025
Q2 		$33.9K Buy
13,840
+2,500
+22% +$12.7K ﹤0.01% 2670
2025
Q1 		$75.6K Buy
11,340
+4,640
+69% +$45.8K ﹤0.01% 2180
2024
Q4 		$84.2K Sell
6,700
-1,800
-21% -$27.1K ﹤0.01% 2066
2024
Q3 		$157K Buy
8,500
+1,000
+13% +$20.5K ﹤0.01% 1648
2024
Q2 		$161K Hold
7,500
– – ﹤0.01% 1547
2024
Q1 		$202K Buy
7,500
+2,500
+50% +$71K ﹤0.01% 1429
2023
Q4 		$150K Hold
5,000
– – ﹤0.01% 1498
2023
Q3 		$102K Buy
5,000
+500
+11% +$9.09K ﹤0.01% 1555
2023
Q2 		$89.4K Hold
4,500
– – ﹤0.01% 1631
2023
Q1 		$77.1K Buy
4,500
+2,500
+125% +$49K ﹤0.01% 1688
2022
Q4 		$39.1K Buy
+2,000
New +$36.8K ﹤0.01% 1940

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Steward Partners Investment Advisory's RCKT Position: Q2 2026 in Review

Steward Partners Investment Advisory held its Rocket Pharmaceuticals (RCKT) position steady in Q2 2026 at 16,340 shares worth $55.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2878.

Steward Partners Investment Advisory first reported a position in RCKT in Q4 2022 and has held it in 15 quarters since. The position peaked at $202K in Q1 2024. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Steward Partners Investment Advisory held 16,340 shares of Rocket Pharmaceuticals worth $55.9K as of Q2 2026.
  • Steward Partners Investment Advisory left its Rocket Pharmaceuticals share count unchanged in Q2 2026.
  • Rocket Pharmaceuticals made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #2878 holding.
  • Steward Partners Investment Advisory first reported a position in Rocket Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Steward Partners Investment Advisory's Rocket Pharmaceuticals position peaked at $202K in Q1 2024.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.